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Abstract
Focal Adhesion Kinase (FAK) is overexpressed in a number of tumors, including breast cancer.
Another marker of breast cancer tumorigenesis is the tumor suppressor gene p53 that is frequently
mutated in breast cancer. In the present study, our aim was to find a correlation between FAK
overexpression, p53 expression and mutation status in a population-based series of invasive breast
cancer tumors from the Carolina Breast Cancer Study. Immunohistochemical analyses of 622
breast cancer tumors revealed that expression of FAK and p53 were highly correlated (P = 0.0002)
and FAK positive tumors were 1.8 times more likely to be p53 positive compared to FAK negative
tumors [odds ratio (OR) = 1.8; 95% Confidence Interval (CI) 1.2 – 2.8, adjusted for age, race and
stage at diagnosis]. Tumors positive for p53 expression showed higher intensity of FAK staining
(P<0.0001) and higher percent of FAK positive staining (P<0.0005). From the same study, we
evaluated 596 breast tumors for mutations in the p53 gene, using SSCP (single strand
conformational polymorphism) and sequencing. Statistical analyses were performed to determine
the correlation between p53 mutation status and FAK expression in these tumors. We found that
FAK expression and p53 mutation were positively correlated (P<0.0001) and FAK positive tumors
were 2.5 times more likely to be p53 mutation positive compared to FAK negative tumors
[adjusted OR = 2.5, 95% CI 1.6–3.9]. This is the first analysis demonstrating a high correlation
between FAK expression and p53 mutations in a population-based series of breast tumors.
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Novelty and Impact: This is the first analysis demonstrating a high correlation between FAK expression and p53 mutations in a
population-based series of breast tumors. Since FAK overexpression highly correlate with p53 mutation, the combined abrogation of
these pathways may be important for breast cancer therapeutics.
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Introduction
Tumor suppressor p53 is one of the major markers of human tumorigenesis and is mutated
in almost 50% of all tumors 1. Following induction by a variety of cell stresses such as DNA
damage, hypoxia, and oncogene activation, p53 up-regulates a number of genes that can
promote cell death and growth arrest, such as p21, Bax, cyclin G, GADD45 (reviewed in 2).
Recently, it was shown that p53 can also repress promoter activities of a number of anti-
apoptotic genes and cell-cycle genes (survivin, cyclin B1, cdc2, cdc25 c, stathmin, Map4,
bcl-2 and FAK) 3.
Focal adhesion kinase (FAK) is a non-receptor cytoplasmic protein tyrosine kinase that
controls a number of cellular signaling pathways, including proliferation, cell spreading,
motility, angiogenesis, invasion and survival 4. FAK is overexpressed in many types of
tumors, including breast cancer tumors 5. We have shown that FAK up-regulation occurred
in early stages of breast tumorigenesis 5, 6. In addition, increased FAK mRNA and protein
expression has been demonstrated in adenomatous tissues and in matched samples of
colorectal carcinoma and liver metastases 7, 8.
The first report on indirect functional link between FAK and tumor suppressor gene p53 was
reported by Ilic et al. 9. The authors demonstrated that p53 controls survival signals from the
extracellular matrix transduced by FAK in anchorage-dependent cells 9. Recently, cloning
and characterization of the FAK promoter demonstrated p53 transcription factor binding
sites that had potential importance for regulation of FAK transcription 3. In addition, we and
other group demonstrated direct physical interaction of the FAK and p53 proteins 10, 11
providing a novel mechanism for FAK-p53-mediated signaling in tumorigenesis 12, 13.
Recently, global characterization of 65,572 p53 ChIP DNA fragments was done on 5-
fluorouracil-treated HCT116 colorectal cancer cells to determine potential targets of
activated p53 14. The authors identified a number of novel targets, including PTK2 (FAK)
that were involved in cell adhesion, migration and metastasis 14. These 5-fluouracil-treated
HCT116 cells inhibited FAK 14, leading the authors to suggest that p53 can suppress
metastasis through repression of FAK. We performed ChIP assays on HCT116 colon cancer
cells and demonstrated that p53 can bind the FAK promoter both in vitro 3 and in vivo 15
and repress its promoter activity 3. Furthermore, recently we demonstrated down-regulation
of FAK mRNA and protein levels by adenoviral overexpression of p53 and by endogenous
induction of p53 with chemotherapy15. The aim of this report was to analyze the p53 status
and FAK expression in a population-based series of breast cancers. We clearly show for the
first time that high FAK expression and the presence of p53 mutations positively correlated
in a population-based series of invasive breast cancer.
Materials and Methods
Study Population
The Carolina Breast Cancer Study (CBCS) is a population-based, case-control study of
breast cancer in African American and white women16, 17. The CBCS included women 20–
74 years of age from 24 contiguous counties of central and eastern North Carolina. This
research was approved by the University of North Carolina School of Medicine IRB and
University of Florida IRB. Women with a first diagnosis of invasive breast cancer (Phase 1
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of the CBCS) were identified by the North Carolina Central Cancer Registry through a rapid
case ascertainment system. Increased cases of African American women and women
younger than 50 years were included so that these subpopulations would represent
approximately 50% of the study population 17.
Tumor specimens for FAK staining
Formalin-fixed, paraffin-embedded tumor blocks were obtained from participating hospital’s
Pathology Departments and tumors were sectioned by the Specialized Programs of Research
Excellence (SPORE) Immunohistochemiostry Core facility. Total 629 breast cancer
formalin-fixed, paraffin-embeded tissue cases were used for FAK immunohistochemical
analysis.
Immunohistochemistry
FAK immuniohistochemistry was performed using the FAK monoclonal antibody 4.47
(Upstate Biotechnology, USA), as described in 16. In brief, slides were heated at 60°C for
one hour prior to deparafinization, rehydration and quenching of endogenous peroxidase
activity (3% hydrogen peroxide in methanol). The hydration process was completed by
rinsing in DAKO TBS buffer (DAKO Corporation, Carpinteria, CA), containing 0.05%
Tween 20 (DAKO Corporation, Carpinteria, CA). During heat-induced epitope recovery,
sections were steam-heated while submerged in antigen retrieval Citra buffer (BioGenex,
San Ramon, CA) for 30 minutes. Sections were blocked in normal horse serum (Vectastatin
Elite Kit, Vector Laboratories, Burlingame, CA) for 15 minutes and then incubated with
anti-FAK 4.47 monoclonal antibody (1:250 dilution) overnight at 4°C in a humidity
chamber. Sections were washed in DAKO TBS buffer containing 0.05% Tween 20 and then
loaded into the DAKO Autostainer for application and incubation of the biotinylated horse
antimouse IgG (Vectastatin Elite Kit, Vector Laboratories, Burlingame, CA) for 30 minutes
at room temperature. The Avidin-biotin complex (Vectastatin Elite Kit, Vector Laboratories,
Burlingame, CA) was applied to the slides for 30 minutes at room temperature. The
chromagenic reaction was performed with SG (Vector Laboratories, Burlingame, CA) for 10
minutes at room temperature. Slides were removed from the autostainer and counterstained
with Nuclear Fast Red (Vector Laboratories, Burlingame, CA) for 10 minutes and
coverslipped with PerMount (Fisher Scientific). Positive and negative controls were
included with each run. P53 monoclonal antibody (clone DO-7; Dako, CA, USA) was used
for p53 immunohistochemical staining, as described in 18. In brief, the slides were dried and
p53 antibody was applied 1:100 dilution to the slides for 30 minutes at 37C. Then slides
were processed the same as above. Control sections were incubated with a comparable
concentration of isotype-matched IgG1 monoclonal antibody, MOPC-21 (Sigma, St Louis,
Mo).
Immunohistochemistry Scoring
A single experienced board certified pathologist scored blindly each tissue section for FAK
expression based on a scoring system that measured intensity (0, none; 1, borderline; 2,
weak; 3, moderate; 4, strong) and percentage of positive cells (1–100), as described in 16.
FAK was considered high with intensity equal 3 or 4 and with percent (%) of positive cells
greater than or equal to 90% and FAK was considered low (0,1 or 2 intensity and/or < 90%
positive cells16,18. Positive p53 was considered as at least 2+ nuclear intensity in > 10% of
cancer cells.
P53 Mutation Screening
Mutations in exons 4–8 of the p53 gene were evaluated by SSCP analysis and DNA
sequencing, as described before 17. P53 positive tumor contained any p53 mutation,
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excluding silent non-clinical-relevant mutations and p53-negative included tumors without
mutation and tumors with silent mutations, as defined in 17.
Statistical analysis
Statistical analyses were performed with SAS statistical software, Version 9.2, SAS Institute
Inc., Cary, NC, USA. Fisher’s exact test was used to determine the correlation between FAK
expression and p53 mutation. Chi-square test was used to determine correlation between
FAK and p53 expression. Unconditional logistic regression was implemented to estimate
odds ratios for the association of high FAK expression and p53 mutation. For OR, odds ratio
and CI confidence interval calculations unadjusted or adjusted for age (11-ordinal variable
value), race (African American, non African American) and stage at diagnosis (1, 2, 3+4)
models were used.
Results and Discussion
In the present report we analyzed p53 status and FAK expression in a population-based
series of breast cancer tumors. We screened 596 breast tumors from Phase I of Carolina
Breast Cancer Study 17 for mutation status and found p53 mutations in 169 patients (28%)
of the 596 tumors. This group we called p53 mutation positive (Table 1). The group did not
include negative silent mutation of p53, as described in 17. Another group 427 (72%) out of
596 included no p53 mutations and silent p53 mutation, called p53 mutation-negative group
(Table 1). Immunohistochemical analysis of FAK expression was performed as described in
16. High FAK expression was considered high with intensity 3+ or 4+ and ≥90% positive
cells and not high (0,1 or 2 intensity and/or <90% positive cells 16. Statistical analysis by
Fisher’s exact test shows that among p53 mutation-positive tumors FAK expression was
high in 38%, while in p53-mutation negative cases FAK expression was high in 18% of
cases and low in 82%. Thus, high FAK expression positively correlated with p53 mutation
(P<0.0001). An example of a breast tumor with hot-spot mutation and FAK expression is
shown on Fig 1. We used logistic regression analysis to calculate odds ratio (OR) and found
that tumors with p53 mutation were significantly more likely to have FAK overexpression
than tumors without p53 mutation (unadjusted OR=2.8; 95% confidence interval CI, 1.8–
4.2); adjusted OR = 2.5, 95% CI 1.6–3.9; (adjusted for age (11- level ordinal variable), race
(African American, non African American) and stage at diagnosis (1, 2, 3+4). Thus, analysis
of 596 breast cancer patients showed that p53 mutation was correlated with high FAK
expression in the breast cancers.
We also performed immunohistochemical analysis of FAK and p53 expression in 622
tumors from the Carolina Breast Cancer Study (Table 2). We found that tumors with high
FAK expression were more likely to be p53-positive (unadjusted OR=2.0, 95% CI 1.4–3.0;
adjusted OR = 1.8, 95% CI 1.2 – 2.8). The correlation was statistically significant (Chi
square test, P=0.0002) (Table 2). P53-positive tumors showed higher intensity of FAK
staining and higher percent of positive cells (Table 2). These data are consistent with data on
endometrial cancers that demonstrated correlation with FAK and p53 overexpression 18.
There were also supporting our data reports that showed a positive correlation between p53
mutation and p53 overexpression in breast cancers 19 20. In addition, p53 mutations and
overexpression has been demonstrated to be a marker of poor patent prognosis and breast
cancer aggressiveness. One of the mechanisms of positive correlation between p53 mutation
and FAK overexpression is based on the repressive function of wild type of p53 on the FAK
promoter 3. Once p53 has either a DNA-binding domain mutation or a frameshift mutation,
it is not able to bind the FAK promoter, so the repression of p53 is abrogated, and FAK
transcription increases due to the non-function of p53.
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In summary, this is the first analysis on population-based series of 596 breast cancer tumors
demonstrating the high positive correlation between p53 expression and mutations with
FAK overexpression and provides an additional basis for FAK-p53 signaling during
tumorigenesis. Since FAK overexpression and p53 mutation are associated with worse
prognosis, the combined abrogation of these pathways will be important for breast cancer
therapeutics.
Abbreviations
FAK Focal Adhesion Kinase
ChIP chromatin immunoprecipitation
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Figure 1. Immunostaining of FAK and p53 expression in breast cancer tumor with p53 mutation
Example of high FAK and p53 staining in breast cancer tumor in patients positive for p53
mutation. Immunostaining of FAK and p53 was performed on different sections of tumors
as described in Materials and Methods. FAK 4.47 antibody was used at dilution 1:250; p53
antibody was used (1:500). High FAK expression and p53 are shown. P53 was
overexpressed in tumor with p53 mutation.
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Table 1
Correlation between FAK and p53 mutations in breast cancer tumors.
FAK expression p53 mutation status
p53 positive (p53+) p53 negative (p53−)
N = 169 N = 427
N (%) N (%)
High FAK 65 (38%) 78 (18%)
Low FAK 104 (62%) 349 (82%)
P<0.0001
OR=2.8 (95% CI, 1.8–4.2)   unadjusted
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Table 2
Correlation between FAK and p53 expression in breast cancer tumors.
FAK expression p53 expression
p53 positive (p53+) p53 negative (p53−)
N = 292 N = 330
N (%) N (%)
High FAK 91 (31%) 60 (18%)
Low FAK 201 (69%) 270 (82%)
OR = 2.0 (95% CI, 1.4–3.0)   unadjusted
OR = 1.8 (95% CI, 1.2–2.8)   adjusted for age, race and stage
P b =0.0002
FAK intensity b Mean Median
p53 expression positive (p53+) 2.5 2.0 0–4
p53 expression negative (p53−) 1.9 2.0 0–4
Pc<0.0001
FAK staining
% positive c Mean Median
p53-positive 71.8% 80 0–99
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